BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10694317)

  • 1. Nail alterations secondary to pactitaxel [corrected] therapy.
    Almagro M; Pozo JD; Garcia J; Vasquez A; Fonseca E
    Eur J Dermatol; 2000 Mar; 10(2):146-7. PubMed ID: 10694317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Yellow nails].
    Auvinet M; Dahan S; Dingremont C; Ollier S; Juchet H; Arlet P
    Rev Med Interne; 1998 May; 19(5):353-4. PubMed ID: 9775172
    [No Abstract]   [Full Text] [Related]  

  • 3. Nail bed dyschromia secondary to docetaxel therapy.
    Jacob CI; Patten SF
    Arch Dermatol; 1998 Sep; 134(9):1167-8. PubMed ID: 9762045
    [No Abstract]   [Full Text] [Related]  

  • 4. Paclitaxel-induced nail changes: possible role of its vehicle (Cremophor EL).
    Minutilli E; Izzo F; Natoli G; Psaila A; Di Filippo F; Terzoli E
    Eur J Dermatol; 2006; 16(6):693-4. PubMed ID: 17229616
    [No Abstract]   [Full Text] [Related]  

  • 5. Nail changes secondary to docetaxel (Taxotere).
    Correia O; Azevedo C; Pinto Ferreira E; Braga Cruz F; Polónia J
    Dermatology; 1999; 198(3):288-90. PubMed ID: 10393455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible paclitaxel-induced vocal cord paralysis with later recall with vinorelbine.
    Choi BS; Robins HI
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):345-6. PubMed ID: 18026678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onycholysis associated with weekly administration of paclitaxel.
    Flory SM; Solimando DA; Webster GF; Dunton CJ; Neufeld JM; Haffey MB
    Ann Pharmacother; 1999 May; 33(5):584-6. PubMed ID: 10369623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodistributed erythema multiforme: paclitaxel-related, photosensitive conditions in patients with cancer.
    Cohen PR
    J Drugs Dermatol; 2009 Jan; 8(1):61-4. PubMed ID: 19180897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel-induced cardiotoxicity. An ultrastructural study.
    Shek TW; Luk IS; Ma L; Cheung KL
    Arch Pathol Lab Med; 1996 Jan; 120(1):89-91. PubMed ID: 8554453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nail toxicity related to taxanes.
    Mourad YA; Matta-Muallem M; Shamseddine A
    Dermatol Online J; 2003 Aug; 9(3):15. PubMed ID: 12952762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel chemotherapy induces transverse superficial loss of the nail plate.
    Llombart-Cussac A; Pivot X; Spielmann M
    Arch Dermatol; 1997 Nov; 133(11):1466-7. PubMed ID: 9371043
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation.
    Yorulmaz A; Dogan M; Artuz F; Zengin N
    Cutan Ocul Toxicol; 2017 Jun; 36(2):135-139. PubMed ID: 27086693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical picture: nail changes secondary to docetaxel.
    Wasner G; Hilpert F; Baron R; Pfisterer J
    Lancet; 2001 Mar; 357(9260):910. PubMed ID: 11289346
    [No Abstract]   [Full Text] [Related]  

  • 14. Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail.
    Paul LJ; Cohen PR
    J Drugs Dermatol; 2012 Feb; 11(2):262-8. PubMed ID: 22270214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading?
    Spazzapan S; Crivellari D; Lombardi D; Scuderi C; Magri MD; Veronesi A; Gatti A
    J Clin Oncol; 2002 Nov; 20(21):4404-5; author reply 4405. PubMed ID: 12409345
    [No Abstract]   [Full Text] [Related]  

  • 17. Peripheral neuropathy in a woman with breast cancer.
    Cianfrocca M; Flatters SJ; Bennett GJ; McNicol E; Relias V; Carr D; Gillis TA
    J Pain; 2006 Jan; 7(1):2-10. PubMed ID: 16414547
    [No Abstract]   [Full Text] [Related]  

  • 18. Subungal abcesses secondary to paclitaxel.
    Albares MP; Belinchón I; Pascual JC; Vergara G; Blanes M; Betlloch I
    Dermatol Online J; 2003 Aug; 9(3):16. PubMed ID: 12952763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature.
    Hussain S; Anderson DN; Salvatti ME; Adamson B; McManus M; Braverman AS
    Cancer; 2000 May; 88(10):2367-71. PubMed ID: 10820360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoleuconychia: A rare reversible entity.
    Sidhu AS; Das L; Singh AS
    Postgrad Med J; 2020 Mar; 96(1133):167. PubMed ID: 31597787
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.